Brokers Set Expectations for Eyegate Pharmaceuticals, Inc.’s Q3 2017 Earnings (NASDAQ:EYEG)
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) – Equities researchers at Zacks Investment Research boosted their Q3 2017 earnings estimates for shares of Eyegate Pharmaceuticals in a note issued to investors on Tuesday. Zacks Investment Research analyst B. Marckx now expects that the specialty pharmaceutical company will post earnings per share of ($0.22) for the quarter, up from their previous forecast of ($0.35). Zacks Investment Research also issued estimates for Eyegate Pharmaceuticals’ Q4 2017 earnings at ($0.22) EPS, FY2017 earnings at ($0.97) EPS, FY2018 earnings at ($0.53) EPS and FY2019 earnings at ($0.42) EPS.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last announced its earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.39) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.39). Eyegate Pharmaceuticals had a negative return on equity of 840.69% and a negative net margin of 1,737.29%. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.22 million. COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/10/brokers-set-expectations-for-eyegate-pharmaceuticals-inc-s-q3-2017-earnings-nasdaqeyeg.html.
EYEG has been the topic of several other research reports. Noble Financial reaffirmed a “buy” rating on shares of Eyegate Pharmaceuticals in a report on Friday, May 19th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Eyegate Pharmaceuticals in a report on Wednesday, June 14th.
Eyegate Pharmaceuticals (NASDAQ EYEG) opened at 1.12 on Thursday. Eyegate Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $3.90. The company’s 50-day moving average price is $1.32 and its 200 day moving average price is $1.86. The stock’s market capitalization is $12.18 million.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Stock Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.